57 related articles for article (PubMed ID: 21397726)
1. Portal pressure predicts outcome and safety of antiviral therapy in cirrhotic patients with hepatitis C virus infection.
Reiberger T; Rutter K; Ferlitsch A; Payer BA; Hofer H; Beinhardt S; Kundi M; Ferenci P; Gangl A; Trauner M; Peck-Radosavljevic M
Clin Gastroenterol Hepatol; 2011 Jul; 9(7):602-8.e1. PubMed ID: 21397726
[TBL] [Abstract][Full Text] [Related]
2. A Machine Learning Approach to Liver Histological Evaluation Predicts Clinically Significant Portal Hypertension in NASH Cirrhosis.
Bosch J; Chung C; Carrasco-Zevallos OM; Harrison SA; Abdelmalek MF; Shiffman ML; Rockey DC; Shanis Z; Juyal D; Pokkalla H; Le QH; Resnick M; Montalto M; Beck AH; Wapinski I; Han L; Jia C; Goodman Z; Afdhal N; Myers RP; Sanyal AJ
Hepatology; 2021 Dec; 74(6):3146-3160. PubMed ID: 34333790
[TBL] [Abstract][Full Text] [Related]
3. Similar performance of liver stiffness measurement and liver surface nodularity for the detection of portal hypertension in patients with hepatocellular carcinoma.
Souhami A; Sartoris R; Rautou PE; Cauchy F; Bouattour M; Durand F; Giannelli V; Gigante E; Castera L; Valla D; Soubrane O; Vilgrain V; Ronot M
JHEP Rep; 2020 Oct; 2(5):100147. PubMed ID: 32885156
[TBL] [Abstract][Full Text] [Related]
4. Novel serum biomarker of Golgi protein 73 for the diagnosis of clinically significant portal hypertension in patients with compensated cirrhosis.
Liu S; Ma J; Chen P; Liu S; Guo Y; Tan M; Guo X; Feng Y; Wang Q; Li W; Yang C; Gao B; Hua Y; Liu N; Song H; He R; Wang R; Gao Q; Liu C; Qi X
J Med Virol; 2024 Jan; 96(1):e29380. PubMed ID: 38235849
[TBL] [Abstract][Full Text] [Related]
5. Changes in Hepatic Venous Pressure Gradient Predict Hepatic Decompensation in Patients Who Achieved Sustained Virologic Response to Interferon-Free Therapy.
Mandorfer M; Kozbial K; Schwabl P; Chromy D; Semmler G; Stättermayer AF; Pinter M; Hernández-Gea V; Fritzer-Szekeres M; Steindl-Munda P; Trauner M; Peck-Radosavljevic M; García-Pagán JC; Ferenci P; Reiberger T
Hepatology; 2020 Mar; 71(3):1023-1036. PubMed ID: 31365764
[TBL] [Abstract][Full Text] [Related]
6. Non-invasive candidate protein signature predicts hepatic venous pressure gradient reduction in cirrhotic patients after sustained virologic response.
Richards SM; Guo F; Zou H; Nigsch F; Baiges A; Pachori A; Zhang Y; Lens S; Pitts R; Finkel N; Loureiro J; Mongeon D; Ma S; Watkins M; Polus F; Albillos A; Tellez L; Martinez-González J; Bañares R; Turon F; Ferrusquía-Acosta J; Perez-Campuzano V; Magaz M; Forns X; Badman M; Sailer AW; Ukomadu C; Hernández-Gea V; Garcia-Pagán JC
Liver Int; 2023 Sep; 43(9):1984-1994. PubMed ID: 37443448
[TBL] [Abstract][Full Text] [Related]
7. Non-invasive liver disease assessment to identify portal hypertension: A systematic review supporting the AASLD Practice Guideline.
Rockey DC; Alsawas M; Duarte-Rojo A; Patel K; Levine D; Asrani SK; Hasan B; Nayfeh T; Alsawaf Y; Saadi S; Malandris K; Murad MH; Sterling RK
Hepatology; 2024 Mar; ():. PubMed ID: 38489516
[TBL] [Abstract][Full Text] [Related]
8. Serum proteomic profiling of patients with compensated advanced chronic liver disease with and without clinically significant portal hypertension.
Pastrovic F; Novak R; Grgurevic I; Hrkac S; Salai G; Zarak M; Grgurevic L
PLoS One; 2024; 19(4):e0301416. PubMed ID: 38603681
[TBL] [Abstract][Full Text] [Related]
9. Metabolomics as a tool to predict the risk of decompensation or liver-related death in patients with compensated cirrhosis.
Nicoară-Farcău O; Lozano JJ; Alonso C; Sidorova J; Villanueva C; Albillos A; Genescà J; Llop E; Calleja JL; Aracil C; Bañares R; Morillas R; Poca M; Peñas B; Augustin S; Tantău M; Thompson M; Perez-Campuzano V; Baiges A; Turon F; Hernández-Gea V; Abraldes JG; Tapias EA; Torres F; Bosch J; García-Pagán JC;
Hepatology; 2023 Jun; 77(6):2052-2062. PubMed ID: 36811400
[TBL] [Abstract][Full Text] [Related]
10. HVPG as a Predictor of Mortality in Non-Critically-Ill Cirrhotic Patients.
Yoo JJ; Kim SG
J Korean Med Sci; 2019 Aug; 34(33):e235. PubMed ID: 31436055
[No Abstract] [Full Text] [Related]
11. Are There Still Difficult-to-Treat Patients with Chronic Hepatitis C in the Era of Direct-Acting Antivirals?
Pabjan P; Brzdęk M; Chrapek M; Dziedzic K; Dobrowolska K; Paluch K; Garbat A; Błoniarczyk P; Reczko K; Stępień P; Zarębska-Michaluk D
Viruses; 2022 Jan; 14(1):. PubMed ID: 35062302
[TBL] [Abstract][Full Text] [Related]
12. von Willebrand factor as a biomarker of clinically significant portal hypertension and severe portal hypertension: a systematic review and meta-analysis.
Zou Z; Yan X; Li C; Li X; Ma X; Zhang C; Ju S; Tian J; Qi X
BMJ Open; 2019 Aug; 9(8):e025656. PubMed ID: 31473610
[TBL] [Abstract][Full Text] [Related]
13. Real-world safety and efficacy of paritaprevir/ritonavir/ombitasvir plus dasabuvir ± ribavirin in patients with hepatitis C virus genotype 1 and advanced hepatic fibrosis or compensated cirrhosis: a multicenter pooled analysis.
Chen CH; Chen CH; Lin CL; Lin CY; Hu TH; Tung SY; Hsieh SY; Lu SN; Chien RN; Hung CH; Sheen IS
Sci Rep; 2019 May; 9(1):7086. PubMed ID: 31068655
[TBL] [Abstract][Full Text] [Related]
14. von Willebrand Factor Antigen Predicts Outcomes in Patients after Liver Resection of Hepatocellular Carcinoma.
Schwarz C; Fitschek F; Mittlböck M; Saukel V; Bota S; Ferlitsch M; Ferlitsch A; Bodingbauer M; Kaczirek K
Gut Liver; 2020 Mar; 14(2):218-224. PubMed ID: 30428508
[TBL] [Abstract][Full Text] [Related]
15. Noninvasive Monitoring of Liver Disease Regression after Hepatitis C Eradication Using Gadoxetic Acid-Enhanced MRI.
Haider L; Mandorfer M; Güngören Z; Reiberger T; Bastati N; Hodge JC; Chromy D; Trauner M; Herold C; Peck-Radosavljevic M; Ba-Ssalamah A
Contrast Media Mol Imaging; 2018; 2018():8489709. PubMed ID: 30116164
[TBL] [Abstract][Full Text] [Related]
16. New resistance-associated substitutions and failure of dual oral therapy with daclatasvir and asunaprevir.
Mawatari S; Oda K; Tabu K; Ijuin S; Kumagai K; Inada Y; Uto H; Hiramine Y; Kure T; Fujisaki K; Hashiguchi M; Hori T; Oshige A; Imanaka D; Saishoji A; Taniyama O; Sakae H; Tamai T; Moriuchi A; Ido A
J Gastroenterol; 2017 Jul; 52(7):855-867. PubMed ID: 28078469
[TBL] [Abstract][Full Text] [Related]
17. Liver stiffness predicts the response to direct-acting antiviral-based therapy against chronic hepatitis C in cirrhotic patients.
Neukam K; Morano-Amado LE; Rivero-Juárez A; Macías J; Granados R; Romero-Palacios A; Márquez M; Merino D; Ortega E; Alados-Arboledas JC; Cucurull J; Omar M; Ryan-Murua P; Pineda JA;
Eur J Clin Microbiol Infect Dis; 2017 May; 36(5):853-861. PubMed ID: 28004322
[TBL] [Abstract][Full Text] [Related]
18. The VITRO Score (Von Willebrand Factor Antigen/Thrombocyte Ratio) as a New Marker for Clinically Significant Portal Hypertension in Comparison to Other Non-Invasive Parameters of Fibrosis Including ELF Test.
Hametner S; Ferlitsch A; Ferlitsch M; Etschmaier A; Schöfl R; Ziachehabi A; Maieron A
PLoS One; 2016; 11(2):e0149230. PubMed ID: 26895398
[TBL] [Abstract][Full Text] [Related]
19. Ombitasvir/paritaprevir/r, dasabuvir and ribavirin for cirrhotic HCV patients with thrombocytopaenia and hypoalbuminaemia.
Forns X; Poordad F; Pedrosa M; Berenguer M; Wedemeyer H; Ferenci P; Shiffman ML; Fried MW; Lovell S; Trinh R; Lopez-Talavera JC; Everson G
Liver Int; 2015 Nov; 35(11):2358-62. PubMed ID: 26248955
[TBL] [Abstract][Full Text] [Related]
20. Predictive value of FIB-4 and APRI versus METAVIR on sustained virologic response in genotype 1 hepatitis C patients.
Ferenci P; Aires R; Beavers KL; Curescu M; Abrão Ferreira PR; Gschwantler M; Ion S; Larrey D; Maticic M; Puoti M; Schuller J; Tornai I; Tusnádi A; Messinger D; Tatsch F; Horban A
Hepatol Int; 2014 Jan; 8(1):83-93. PubMed ID: 26202409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
